Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays

被引:0
作者
Kristina Schwamborn
Johannes U Ammann
Ruth Knüchel
Arndt Hartmann
Gustavo Baretton
Felix Lasitschka
Peter Schirmacher
Till Braunschweig
Robert Tauber
Franziska Erlmeier
Stefanie Hieke-Schulz
Wilko Weichert
机构
[1] Technische Universität München,Institute of Pathology
[2] Roche Pharma AG,Institute of Pathology
[3] Uniklinik RWTH Aachen,Institute of Pathology
[4] Universität Erlangen-Nürnberg,Institute of Pathology
[5] Universitätsklinikum Carl Gustav Carus Dresden,Institute of Pathology
[6] Universitätsklinikum Heidelberg,Department of Urology
[7] Institut für Pathologie,Institute of Pathology
[8] Dres. med.,undefined
[9] Kaufmann und Wilke,undefined
[10] Technische Universität München,undefined
[11] Technische Universität München and Member of the German Cancer Consortium (DKTK),undefined
来源
Virchows Archiv | 2019年 / 475卷
关键词
Programmed death-ligand 1; PD-L1; Urothelial bladder cancer; Immunohistochemistry; Tumor-infiltrating immune cells;
D O I
暂无
中图分类号
学科分类号
摘要
Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) correlated in several studies with PD-L1/programmed death-1 (PD-1) checkpoint inhibitor efficacy. Since June 2018, a positive PD-L1 status is required for atezolizumab or pembrolizumab treatment of patients with advanced or metastasized urothelial bladder cancer, who are ineligible for cisplatin-containing therapy. We examined technical comparability and inter-reader agreement of four clinically developed PD-L1 assays in locally advanced disease. Archived, formalin-fixed, paraffin-embedded sections from 30 patients (73.3% cystectomies, 26.7% transurethral resections) were stained by PD-L1 immunohistochemistry using VENTANA SP142, VENTANA SP263, DAKO 22C3, and DAKO 28-8 at two sites per manufacturers’ protocols and scored blinded at five sites for PD-L1 expression on IC (% per tumor area) and TC (%). Small, non-significant inter-assay differences were observed for IC. For TC, SP142 showed significantly lower staining percentages. Pairwise comparisons revealed − 0.3 to 1.6% differences in adjusted means between assays for IC, and for TC, − 10.5 to − 7.8% (SP142 versus others) and − 1.9 to 2.7% (other comparisons). Inter-reader and inter-assay agreement was moderate to high for both IC and TC. Allocation to binary cutoffs (1%, 5%, 10%) showed substantial to high Kappa agreement scores (0.440–0.923) for IC and TC between assays for each reader. This first multicenter study, with five independent readers blinded with respect to the assay used, suggests that all four currently clinically relevant assays are analytically similar for evaluation of PD-L1-stained IC and three (SP263, 22C3, and 28-8) for PD-L1-stained TC. Inter-observer agreement for trained readers in scoring of both IC and TC positivity was generally high.
引用
收藏
页码:599 / 608
页数:9
相关论文
共 362 条
[1]  
Antoni S(2017)Bladder cancer incidence and mortality: a global overview and recent trends Eur Urol 71 96-108
[2]  
Ferlay J(2017)Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) European Urology 71 281-289
[3]  
Soerjomataram I(2012)Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 J Clin Oncol 30 191-199
[4]  
Znaor A(2005)Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 4602-4608
[5]  
Jemal A(2013)Oncology meets immunology: the cancer-immunity cycle Immunity 39 1-10
[6]  
Bray F(2017)Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Lancet 389 67-76
[7]  
Necchi Andrea(2017)Pembrolizumab as second-line therapy for advanced urothelial carcinoma N Engl J Med 376 1015-1026
[8]  
Sonpavde Guru(2016)Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 387 1909-1920
[9]  
Lo Vullo Salvatore(2017)Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study Ann Oncol 28 3044-3050
[10]  
Giardiello Daniele(2014)MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 558-562